Features of Pharmacotherapy of Hepatic Encephalopathy Manifestations in Liver Cirrhosis

Abstract

The aim of this work is to study the effect of drug mebikar on the clinical manifestations of hepatic encephalopathy in patients with liver cirrhosis. The study involved 34 patients with cirrhosis of different etiologies. The average age of the examined patients was (48.5±0.9) years, that prevailed patients of working age, indicating the medical and social significance of the problem of early diagnosis and adequate treatment of cirrhosis. One of the most frequent complications of cirrhosis is hepatic encephalopathy. In addition to conventional clinical and laboratory findings in patients with liver cirrhosis, severities of hepatic encephalopathy were determined according to West-Haven criteria before and after treatment. In patients with liver cirrhosis was established the presence of latent or clinically expressed hepatic encephalopathy. The treatment of the control group of patients consisted of the following drugs: essential phospholipids, mixture of sorbitol and major ions, arginine glutamate, furosemide, verospiron, lactulose, amoxicillin trihydrate and lansoprazole. In the complex treatment of the main group of patients medicine mebikar was administered additionally. Analysis of the clinical manifestations of hepatic encephalopathy showed a marked improvement in patients who received additional treatment with mebikar. Specifically, the incidences of mood changes as well as anxiety decreased in this group on average of 38% compared with those patients without an additional treatment with mebikar. Also, sleep disturbances in the main group was observed to be lower by 7.2% compared to those in the control group. Inclusion in the treatment of patients with liver cirrhosis, the drug mebikar -a daytime tranquilizer with anxiolytic properties reduces neurotic disorders, improves emotional state which may indicate a regression in the manifestations of hepatic encephalopathy thereby improving the quality of life of patients and thus substantiating an expedient inclusion of mebikar an anxiolytic drug to the complex therapy of patients with liver cirrhosis.